THERAPY DOSSIER · th-f9a7ef4440d5

Plasma-based biomaterial (platelet-enriched human plasma, freeze-dried and crosslinked, at 10% by weight in Aquaphor)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30576033 ↗2018Mixed findings

Plasma-based biomaterials for the treatment of cutaneous radiation injury.

MouseRadiationBALB/cMalen = 22 per group, total 44; 5 animals lost to anaesthesia death…Topical, followed by bandaging0.3 ml of paste per application, spread as a thin film over…Initiated within 24 h following radiation exposure

Model: Cutaneous radiation injury: a 2 cm diameter circle of dorsal skin exposed through a lead shield to a single dose of 35 Gy using an RS 2000 biological irradiator with 165 kV x-rays

Wound closure was significantly better with the plasma-based biomaterial at 12, 13 and 14 weeks post-maximum wound area (14.1 +/- 5.2% vs 34.3 +/- 6.1%; 12.1 +/- 3.9% vs 29.2 +/- 7.0%; 5.7 +/- 3.7% vs 20.7 +/- 8.2%, all p < 0.05). Peak wound size did not differ (p = 0.08). Chronic wounds occurred i…

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…